| Literature DB >> 20728948 |
Bassem Yamout1, Roula Hourani, Haytham Salti, Wissam Barada, Taghrid El-Hajj, Aghiad Al-Kutoubi, Aline Herlopian, Elizabeth Kfoury Baz, Rami Mahfouz, Rima Khalil-Hamdan, Nabeela M A Kreidieh, Marwan El-Sabban, Ali Bazarbachi.
Abstract
We explore the safety, and therapeutic benefit of intrathecal injection of ex-vivo expanded autologous bone marrow derived mesenchymal stem cells (BM-MSCs) in 10 patients with advanced multiple sclerosis (MS). Patients were assessed at 3, 6 and 12 months. Assessment at 3-6 months revealed Expanded Disability Scale Score (EDSS) improvement in 5/7, stabilization in 1/7, and worsening in 1/7 patients. MRI at 3 months revealed new or enlarging lesions in 5/7 and Gadolinium (Gd+) enhancing lesions in 3/7 patients. Vision and low contrast sensitivity testing at 3 months showed improvement in 5/6 and worsening in 1/6 patients. Early results show hints of clinical but not radiological efficacy and evidence of safety with no serious adverse events.Entities:
Mesh：
Year: 2010 PMID： 20728948 DOI： 10.1016/j.jneuroim.2010.07.013
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478